General Information
Carmot Obesity-DM2 104 (XC45544)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants who are Overweight or Obese with Type 2 Diabetes Mellitus.
| Protocol | CT-388-104 (XC45544) |
|---|---|
| Identifier | |
| UID | 3b8b1e7b-ea4b-48d8-a889-01f5e9c5f0e3 |
| Status | Follow-up |
| Phase | 2 |
| Category | Diabetes Type2/Obesity / Adult |
| Launch Year | 2024 |
| NCT Number | - |
| Created | 2024-08-15 11:59 |
| Last Updated | 2025-08-18 20:28 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2025-08-13 | No |
| Enrollment Open | 2025-01-07 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2024-12-18 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | No | |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Andujo, Darlene | DCano | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Carmot Therapeutics |
|---|---|
| Division | Carmot Therapeutics |
| Team | Carmot Therapeutics |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | ICON |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | PaleGoldenrod |
| Currency | - |
